FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1967909716> ?p ?o ?g. }

• W1967909716 abstract "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, ILAntigens that are tumor-specific or over-expressed on cancer cells represent opportunities for developing target-specific antibody-based therapeutics. Utilizing a non-target-biased intact cell-based immunization approach, we have generated greater than 1600 mAbs to cell-surface proteins that are expressed on cancer cells. A subset of the mAbs exhibit differential reactivity to tumor cells compared to normal cells. One of the differentially expressed proteins identified was B7-H3 (also referred to as CD276). B7-H3 is a member of the B7 family of immune regulatory proteins. Over-expression of B7-H3 has been correlated with disease severity and outcome in a growing number of cancer types, and several lines of evidence support a functional role for B7-H3 in cancer. In this report we describe the development of a humanized anti-B7-H3 mAb, designated MGA271, which bears an engineered Fc domain that imparts enhanced antibody-dependent cellular cytotoxicity (ADCC) through increased affinity for the human activating Fc-gamma receptor IIIA (CD16A) and decreased affinity for the human inhibitory Fc-gamma receptor IIB (CD32B). MGA271 displays strong reactivity to multiple tumors including kidney, prostate, pancreatic, breast, colon, gastric and ovarian cancer as well as melanoma, but limited reactivity toward normal human tissues. Independently of the donor's CD16A genotype, MGA271 mediates ADCC in vitro against human tumor cell lines representing these tumor types, as well as to human lung and gastrointestinal cell lines that exhibit properties of cancer stem cells. MGA271 exhibits potent anti-tumor activity toward B7-H3-expressing tumor xenografts in mice knocked-out for the murine CD16 gene and transgenic for the low affinity allele of human CD16A. Single- and repeat-dose toxicology studies were carried out in cynomolgus monkeys and no significant test article-related safety findings were observed. Taken together, these data support the clinical development of MGA271 for the treatment of patients who have B7-H3-expressing cancers.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2725. doi:1538-7445.AM2012-2725" @default.
• W1967909716 created "2016-06-24" @default.
• W1967909716 creator A5001873949 @default.
• W1967909716 creator A5002630416 @default.
• W1967909716 creator A5007144110 @default.
• W1967909716 creator A5009027578 @default.
• W1967909716 creator A5017521861 @default.
• W1967909716 creator A5023294934 @default.
• W1967909716 creator A5025376488 @default.
• W1967909716 creator A5031117799 @default.
• W1967909716 creator A5037353634 @default.
• W1967909716 creator A5037458498 @default.
• W1967909716 creator A5044573330 @default.
• W1967909716 creator A5053693367 @default.
• W1967909716 creator A5056696051 @default.
• W1967909716 creator A5058157301 @default.
• W1967909716 creator A5061388073 @default.
• W1967909716 creator A5065283960 @default.
• W1967909716 creator A5067757338 @default.
• W1967909716 creator A5077925652 @default.
• W1967909716 creator A5080629319 @default.
• W1967909716 creator A5081117163 @default.
• W1967909716 creator A5082960633 @default.
• W1967909716 creator A5084217116 @default.
• W1967909716 date "2012-04-15" @default.
• W1967909716 modified "2023-09-23" @default.
• W1967909716 title "Abstract 2725: Preclinical development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent anti-tumor activity" @default.
• W1967909716 doi "https://doi.org/10.1158/1538-7445.am2012-2725" @default.
• W1967909716 hasPublicationYear "2012" @default.
• W1967909716 type Work @default.
• W1967909716 sameAs 1967909716 @default.
• W1967909716 citedByCount "2" @default.
• W1967909716 countsByYear W19679097162018 @default.
• W1967909716 countsByYear W19679097162019 @default.
• W1967909716 crossrefType "proceedings-article" @default.
• W1967909716 hasAuthorship W1967909716A5001873949 @default.
• W1967909716 hasAuthorship W1967909716A5002630416 @default.
• W1967909716 hasAuthorship W1967909716A5007144110 @default.
• W1967909716 hasAuthorship W1967909716A5009027578 @default.
• W1967909716 hasAuthorship W1967909716A5017521861 @default.
• W1967909716 hasAuthorship W1967909716A5023294934 @default.
• W1967909716 hasAuthorship W1967909716A5025376488 @default.
• W1967909716 hasAuthorship W1967909716A5031117799 @default.
• W1967909716 hasAuthorship W1967909716A5037353634 @default.
• W1967909716 hasAuthorship W1967909716A5037458498 @default.
• W1967909716 hasAuthorship W1967909716A5044573330 @default.
• W1967909716 hasAuthorship W1967909716A5053693367 @default.
• W1967909716 hasAuthorship W1967909716A5056696051 @default.
• W1967909716 hasAuthorship W1967909716A5058157301 @default.
• W1967909716 hasAuthorship W1967909716A5061388073 @default.
• W1967909716 hasAuthorship W1967909716A5065283960 @default.
• W1967909716 hasAuthorship W1967909716A5067757338 @default.
• W1967909716 hasAuthorship W1967909716A5077925652 @default.
• W1967909716 hasAuthorship W1967909716A5080629319 @default.
• W1967909716 hasAuthorship W1967909716A5081117163 @default.
• W1967909716 hasAuthorship W1967909716A5082960633 @default.
• W1967909716 hasAuthorship W1967909716A5084217116 @default.
• W1967909716 hasConcept C121608353 @default.
• W1967909716 hasConcept C126322002 @default.
• W1967909716 hasConcept C147483822 @default.
• W1967909716 hasConcept C159654299 @default.
• W1967909716 hasConcept C203014093 @default.
• W1967909716 hasConcept C2779931124 @default.
• W1967909716 hasConcept C2780192828 @default.
• W1967909716 hasConcept C2780427987 @default.
• W1967909716 hasConcept C40677261 @default.
• W1967909716 hasConcept C502942594 @default.
• W1967909716 hasConcept C542903549 @default.
• W1967909716 hasConcept C71924100 @default.
• W1967909716 hasConcept C86803240 @default.
• W1967909716 hasConcept C8891405 @default.
• W1967909716 hasConceptScore W1967909716C121608353 @default.
• W1967909716 hasConceptScore W1967909716C126322002 @default.
• W1967909716 hasConceptScore W1967909716C147483822 @default.
• W1967909716 hasConceptScore W1967909716C159654299 @default.
• W1967909716 hasConceptScore W1967909716C203014093 @default.
• W1967909716 hasConceptScore W1967909716C2779931124 @default.
• W1967909716 hasConceptScore W1967909716C2780192828 @default.
• W1967909716 hasConceptScore W1967909716C2780427987 @default.
• W1967909716 hasConceptScore W1967909716C40677261 @default.
• W1967909716 hasConceptScore W1967909716C502942594 @default.
• W1967909716 hasConceptScore W1967909716C542903549 @default.
• W1967909716 hasConceptScore W1967909716C71924100 @default.
• W1967909716 hasConceptScore W1967909716C86803240 @default.
• W1967909716 hasConceptScore W1967909716C8891405 @default.
• W1967909716 hasLocation W19679097161 @default.
• W1967909716 hasOpenAccess W1967909716 @default.
• W1967909716 hasPrimaryLocation W19679097161 @default.
• W1967909716 hasRelatedWork W1974972432 @default.
• W1967909716 hasRelatedWork W2079997015 @default.
• W1967909716 hasRelatedWork W2081960149 @default.
• W1967909716 hasRelatedWork W2162743871 @default.
• W1967909716 hasRelatedWork W2324624050 @default.
• W1967909716 hasRelatedWork W2400578715 @default.
• W1967909716 hasRelatedWork W2469368995 @default.
• W1967909716 hasRelatedWork W2489250614 @default.
• W1967909716 hasRelatedWork W2499921140 @default.
• W1967909716 hasRelatedWork W2560882294 @default.
• W1967909716 hasRelatedWork W2729668509 @default.
• W1967909716 hasRelatedWork W2740554793 @default.

• next